{'fraction_non_alphanumeric': 0.00822481151473612, 'fraction_numerical': 0.0, 'mean_word_length': 6.1568627450980395, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Analysis of significance of mitochondrial dysfunction in the pathogenesis of diseases of the central nervous system

One of the promising therapy areas for many diseases of the central nervous system is the search for agents of selective effect on mitochondria. Both the mitochondria themselves and the mitochondrial metabolism of the transformed cell of the central nervous system and activation of energy metabolism by reprogrammed mitochondria give impetus for the development of mitochondrial pharmacology to use the special properties of transformed cells mitochondria as targets for neuroprotective and neuroplastic effects. In this review, we analyse literary sources of domestic and foreign authors about the influence of mitochondrial dysfunction on various links in the pathogenesis of central nervous system diseases. Based on currently available data, scientists divided all signs of mitochondrial dysfunction in schizophrenia into three groups: morphological disorders of mitochondria, signs of a violation of the oxidative phosphorylation system and dysregulation of genes responsible for mitochondrial proteins. The therapeutic effect of drugs for central nervous system disorders should focus on reducing the accumulation of metabolic products and tissue breakdown, restoring mitochondrial functions and synaptic plasticity, and protecting mitochondria from toxic effects, thereby alleviating cognitive disorders with a neuroprotective effect.